Visualizing the Evolution of Evidence: Cumulative Network Meta-Analyses of New Generation Antidepressants in the Last 40 Years

Autor/inn/en	Luo, Yan; Chaimani, Anna; Furukawa, Toshi A.; Kataoka, Yuki; Ogawa, Yusuke; Cipriani, Andrea; Salanti, Georgia
Titel	Visualizing the Evolution of Evidence: Cumulative Network Meta-Analyses of New Generation Antidepressants in the Last 40 Years
Quelle	In: Research Synthesis Methods, 12 (2021) 1, S.74-85 (12 Seiten)Infoseite zur Zeitschrift PDF als Volltext Verfügbarkeit
Zusatzinformation	ORCID (Luo, Yan)
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1759-2879
DOI	10.1002/jrsm.1413
Schlagwörter	Networks; Network Analysis; Meta Analysis; Drug Therapy; Depression (Psychology); Outcomes of Treatment; Evidence; Computer Oriented Programs; Visualization + Suchen Sie Ihr Suchwort? Netzplantechnik; Meta-analysis; Metaanalyse; Evidenz; Computerprogramm; Visualisation; Visualisierung
Abstract	It is often challenging to present the available evidence in a timely and comprehensible manner. We aimed to visualize the evolution of evidence about antidepressants for depression by conducting cumulative network meta-analyses (NMAs) and to examine whether it could have helped the selection of optimal drugs. We built a Shiny web application that performs and presents cumulative NMAs based on R netmeta. We used a comprehensive dataset of double-blind randomized controlled trials of 21 antidepressants in the acute treatment of major depression. The primary outcomes were efficacy (treatment response) and acceptability (all-cause discontinuation), and treatment effects were summarized via odds ratios. We evaluated the confidence in evidence using the CINeMA (Confidence in Network Meta-Analysis) framework for a series of consecutive NMAs. Users can change several conditions for the analysis, such as the period of synthesis, among the others. We present the league tables and two-dimensional plots that combine efficacy, acceptability and level of confidence in the evidence together, for NMAs conducted in 1990, 1995, 2000, 2005, 2010, and 2016. They reveal that through the past four decades, newly approved drugs often showed initially exaggerated results, which tended to diminish and stabilize after approximately a decade. Over the years, the drugs with relative superiority changed dramatically; but as the evidence network grew larger and better connected, the overall confidence improved. The Shiny app visualizes how evidence evolved over years, emphasizing the need for a careful interpretation of relative effects between drugs, especially for the potentially amplified performance of newly approved drugs. (As Provided).
Anmerkungen	Wiley. Available from: John Wiley & Sons, Inc. 111 River Street, Hoboken, NJ 07030. Tel: 800-835-6770; e-mail: cs-journals@wiley.com; Web site: https://www.wiley.com/en-us
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2024/1/01